Focused on rare diseases, this biopharmaceutical company develops therapies for unmet medical needs, with its lead product targeting pulmonary conditions. Investors monitor Insmed for its pipeline progress and commercialization potential in niche markets.
3 members of Congress have disclosed 10 trades in Insmed Incorporated (INSM), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 7 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-03 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-09-22 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-08-08 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-07-07 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-06-16 | Josh Gottheimer | buy | $1K – $15K |
| 2025-04-09 | Josh Gottheimer | sell | $1K – $15K |
| 2024-06-21 | Josh Gottheimer | sell | $1K – $15K |
| 2024-05-28 | Josh Gottheimer | sell | $1K – $15K |
| 2022-12-06 | Josh Gottheimer | buy | $1K – $15K |
| 2020-03-30 | Kurt Schrader | buy | $1K – $15K |